Hepatorenal Syndrome. Hepatorenal syndrome
Conditions
Interventions
Intervention 1: Intervention group: Patients receiving Noradrenaline and Albumin treatment/ In this group, patients with Hepatorenal Syndrome were treated with Noradrenaline at an initial dose of 1 mg
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Diagnosis based on modified HRS diagnostic criteria in 2007: Cirrhosis with ascites and increased serum creatinine level (>1.5 mg/dL) with non-recovery up to 48 hours after diuretic discontinuation and volume increase with albumin Absence of shock Not receiving nephrotoxic drugs Absence of kidney parenchymal disease or obstructive uropathy in laboratory and ultrasound assessment Doubling of creatinine level to more than 2.5 mg/dL in 2 weeks or less
Exclusion criteria
Exclusion criteria: History of coronary disease and evidence of ventricular arrhythmia or cardiomyopathy obtained based on history taking, assessment of risk factors, physical examination, echocardiography and radiography.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of serum creatinine level below 1.5 mg. Timepoint: Before the intervention and days 1, 3, 7 and 14. Method of measurement: Blood and urine samples.;Increase in 4-hour urine output above 200 ml. Timepoint: Before the intervention and days 1, 3, 7 and 14. Method of measurement: Blood and urine samples.;Statistically significant improvement in serum creatinine and sodium levels. Timepoint: Before the intervention and days 1, 3, 7 and 14. Method of measurement: Blood and urine samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment of hepatorenal syndrome and mortality rate. Timepoint: Beginning and end of day 14. Method of measurement: Blood/urine samples and bedside examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Maqsoudloo
Gorgan University of Medical Sciences
Outcome results
None listed